Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

TMK reported for 6 months of 2023 by IFRS

8/28/23 TRMK

SuperJet International wants a European certificate for the SSJ 100

8/28/23 UNAC

Volgogradenergosbyt reported for 6 months of 2023 by IFRS

8/28/23 VGSB

NPO Nauka reported for 6 months of 2023 by IFRS

8/28/23 NAUK

Nauka-Svyaz reported for 6 months of 2023 by IFRS

8/28/23 NSVZ

RSC Energia reported for 6 months of 2023 by IFRS

8/28/23 RKKE

TGC-14 reported for 6 months of 2023 by IFRS

8/28/23 TGKN

TGC-2 reported for 6 months of 2023 by IFRS

8/28/23 TGKB

Softline started exchanging receipts for shares

8/28/23 SFTL

Softline started exchanging receipts for shares

8/28/23 SOFL